Clinical Implications of Interleukin-17 as a Hepato-Dermal Link in Patients With Psoriasis and Concomitant Steatotic Liver Disease
Open Access
- 14 October 2026
- journal article
- review article
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Abstract
Psoriasis is increasingly recognized as a systemic inflammatory disease with impacts beyond the skin and joints. Metabolic dysfunction-associated steatotic liver disease (MASLD) and excessive alcohol consumption are common in the psoriasis population, affecting up to two-thirds of patients. Interleukin-17 (IL-17) has been identified as a potential key pro-inflammatory link between psoriasis and MASLD. IL-17 levels have been positively correlated with progression of MASLD to more advanced forms of liver disease, including steatohepatitis, cirrhosis and hepatocellular carcinoma. Given the high prevalence of concurrent psoriasis and liver disease, dermatologists should have an elevated index of suspicion of MASLD in patients with psoriasis, particularly those with concomitant metabolic risk factors and/or excessive alcohol consumption. Using 3 parameters, the Fibrosis-4 index is a validated, non-invasive screening tool that can be implemented in clinical practice. With the wide variety of therapeutics available to treat psoriasis, practitioners should be mindful of systemic agents carrying potential hepatotoxic adverse effects and could consider instead implementation of advanced therapies that have neutral or potentially beneficial effects on the liver. There is emerging data, pending larger prospective confirmatory studies, that support consideration of IL-17 inhibitors as a reasonable option in appropriate patients with or at risk of MASLD.Keywords
Funding Information
- Bausch Health
This publication has 55 references indexed in Scilit:
- Projected Trends in Metabolic Dysfunction–Associated Steatotic Liver Disease Mortality Through 2040JAMA Network Open, 2025
- Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular DiseaseCurrent Hypertension Reports, 2023
- Alcohol and Psoriasis for the Dermatologist: Know, Screen, InterveneAmerican Journal of Clinical Dermatology, 2022
- Psoriasis Prevalence in Adults in the United StatesJAMA Dermatology, 2021
- Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversiesAutoimmunity Reviews, 2020
- Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patientsClinical Rheumatology, 2019
- IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseasesAutoimmunity Reviews, 2018
- Psoriasis e hígado graso no alcohólicoActas Dermo-Sifiliograficas, 2017
- Hepatotoxicity Associated with the Use of Anti-TNF-α AgentsDrug Safety, 2015
- The interleukin-17 pathway is involved in human alcoholic liver disease # †Hepatology, 2009